Mandate

Vinge has assisted Boliden in the acquisition of the Neves-Corvo and Zinkgruvan mines from Lundin Mining

Boliden has entered into a definitive agreement with Lundin Mining to acquire the Neves-Corvo mine in Portugal and the Zinkgruvan mine in Sweden. The upfront cash consideration for the entities is USD 1,300 m plus contingent payments that can reach up to USD 150 m, on a cash and debt-free basis. The transaction, that considerably strengthens Boliden's mine production as well as internal zinc and copper concentrate supply, is subject to customary regulatory approvals.

Vinge's M&A team was led by Ulrich Ziche and consisted of Maria Dahlin Kolvik, Egil Svensson, and Helena Liljenberg (M&A), Johan Cederblad (Environment), Niclas Winnberg (Real Estate), Emil Lindwall and Louisa Fagarasan (Employment), Victor Ericsson (Tax), Mario Saad (Commercial Agreements), and Johanna Engström (Transaction Support), while the Capital Markets team was led by Jesper Schönbeck and consisted of Amanda Knutsson, Joel Wahlberg, Joel Magnusson, and Adrian Filipovic.

For details of the transaction reference is made to Boliden’s press release, find it here

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025